Asset
BBP-398
BridgeBio Pharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04528836 | phase1 | terminated | 2020-11-12 | 2024-03-22 | Navire Pharma Inc., a BridgeBio company | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors |
| NCT05480865 | phase1 | terminated | 2022-07-06 | 2024-08-22 | Navire Pharma Inc., a BridgeBio company | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation |
FDA applications (0)
This company has no applications containing this asset.